Long-term follow-up of IgM monoclonal gammopathy of undetermined significance

Robert A. Kyle, Terry M Therneau, S Vincent Rajkumar, J. R. Offord, D. R. Larson, M. F. Plevak, L. J. Melton

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lymphoma or a related disorder assessed by the Kaplan-Meier method. Patients were followed for a total of 1,567 person-years (median, 6.3 years per subject). Seventeen patients developed lymphoma (relative risk [RR], 14.8) and six progressed to Waldenstrom's macroglobulinemia (RR, 262), while three developed primary amyloidosis (RR, 16.3) and three others had chronic lymphocytic leukemia (RR, 5.7). The relative risk of progression was 16-fold higher in the IgM MGUS patients compared to the white population of the Iowa Surveillance, Epidemiology, and End Results (SEER) program. The risk of progression of MGUS of IgM type to lymphoma or related disorders averaged 1.5% per year throughout the period of observation.

Original languageEnglish (US)
Pages (from-to)169-171
Number of pages3
JournalSeminars in Oncology
Volume30
Issue number2
DOIs
StatePublished - Apr 2003

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Immunoglobulin M
Lymphoma
Population Surveillance
SEER Program
Waldenstrom Macroglobulinemia
B-Cell Chronic Lymphocytic Leukemia
Observation

ASJC Scopus subject areas

  • Oncology

Cite this

Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. / Kyle, Robert A.; Therneau, Terry M; Rajkumar, S Vincent; Offord, J. R.; Larson, D. R.; Plevak, M. F.; Melton, L. J.

In: Seminars in Oncology, Vol. 30, No. 2, 04.2003, p. 169-171.

Research output: Contribution to journalArticle

Kyle, Robert A. ; Therneau, Terry M ; Rajkumar, S Vincent ; Offord, J. R. ; Larson, D. R. ; Plevak, M. F. ; Melton, L. J. / Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. In: Seminars in Oncology. 2003 ; Vol. 30, No. 2. pp. 169-171.
@article{76a9080f0dd94204b74edcd4c451c816,
title = "Long-term follow-up of IgM monoclonal gammopathy of undetermined significance",
abstract = "The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lymphoma or a related disorder assessed by the Kaplan-Meier method. Patients were followed for a total of 1,567 person-years (median, 6.3 years per subject). Seventeen patients developed lymphoma (relative risk [RR], 14.8) and six progressed to Waldenstrom's macroglobulinemia (RR, 262), while three developed primary amyloidosis (RR, 16.3) and three others had chronic lymphocytic leukemia (RR, 5.7). The relative risk of progression was 16-fold higher in the IgM MGUS patients compared to the white population of the Iowa Surveillance, Epidemiology, and End Results (SEER) program. The risk of progression of MGUS of IgM type to lymphoma or related disorders averaged 1.5{\%} per year throughout the period of observation.",
author = "Kyle, {Robert A.} and Therneau, {Terry M} and Rajkumar, {S Vincent} and Offord, {J. R.} and Larson, {D. R.} and Plevak, {M. F.} and Melton, {L. J.}",
year = "2003",
month = "4",
doi = "10.1053/sonc.2003.50062",
language = "English (US)",
volume = "30",
pages = "169--171",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Long-term follow-up of IgM monoclonal gammopathy of undetermined significance

AU - Kyle, Robert A.

AU - Therneau, Terry M

AU - Rajkumar, S Vincent

AU - Offord, J. R.

AU - Larson, D. R.

AU - Plevak, M. F.

AU - Melton, L. J.

PY - 2003/4

Y1 - 2003/4

N2 - The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lymphoma or a related disorder assessed by the Kaplan-Meier method. Patients were followed for a total of 1,567 person-years (median, 6.3 years per subject). Seventeen patients developed lymphoma (relative risk [RR], 14.8) and six progressed to Waldenstrom's macroglobulinemia (RR, 262), while three developed primary amyloidosis (RR, 16.3) and three others had chronic lymphocytic leukemia (RR, 5.7). The relative risk of progression was 16-fold higher in the IgM MGUS patients compared to the white population of the Iowa Surveillance, Epidemiology, and End Results (SEER) program. The risk of progression of MGUS of IgM type to lymphoma or related disorders averaged 1.5% per year throughout the period of observation.

AB - The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lymphoma or a related disorder assessed by the Kaplan-Meier method. Patients were followed for a total of 1,567 person-years (median, 6.3 years per subject). Seventeen patients developed lymphoma (relative risk [RR], 14.8) and six progressed to Waldenstrom's macroglobulinemia (RR, 262), while three developed primary amyloidosis (RR, 16.3) and three others had chronic lymphocytic leukemia (RR, 5.7). The relative risk of progression was 16-fold higher in the IgM MGUS patients compared to the white population of the Iowa Surveillance, Epidemiology, and End Results (SEER) program. The risk of progression of MGUS of IgM type to lymphoma or related disorders averaged 1.5% per year throughout the period of observation.

UR - http://www.scopus.com/inward/record.url?scp=0037397825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037397825&partnerID=8YFLogxK

U2 - 10.1053/sonc.2003.50062

DO - 10.1053/sonc.2003.50062

M3 - Article

C2 - 12720130

AN - SCOPUS:0037397825

VL - 30

SP - 169

EP - 171

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -